Once Oxyglobin achieves its purpose for animals and satisfies the veterinary doctors and pet owners, the success of this product will help Biopure to easily launch Hemopure and attract the human market. Biopure would also lose out on the potential revenues it will generate to increase production capacity for Hemopure. Composition is the list of ingredients which combinedly form a medicine. While donor dogs are the largest source of transfused blood, the costs to provide this service are prohibitive for many care providers and unknown by the ones using it. We will use trade publication and trade shows for our pull strategy in order to attract attention from Veterinarians.
First, it is important to decide whether the market will accept Hemopure at a price point that is substantially greater than Oxyglobin. Metabolized in the tissues, becoming a co-enzyme form - adenosylcobalamin which is the active form of cyanocobalamin. A blood transfusion is not contraindicated in dogs which receive Oxyglobin ® nor is Oxyglobin ® contraindicated in dogs which have previously received a blood transfusion. Severe kidney disease may make it necessary to reduce or omit chromium and Oxyglobin Zinc Sulfate doses because these elements are primarily eliminated in the urine. Additionally, the emerging and growing necessity for blood substitutes will yield great demand in the following years which will translate to higher selling prices for Biopure, all things equal.
This manufacturer direct model will require Biopure to recruit and maintain a sales force. The treatment outcome for these episodes was rated effective in all cases except one. The safety and efficacy of Oxyglobin ® have not been evaluated in dogs with disseminated intravascular coagulopathy, thrombocytopenia with active bleeding, hemoglobinemia and hemoglobinuria, or autoagglutination. And and aging population double of what it is today by 2030 in need of Red Blood Cells to treat certain conditions like chronic anemia and acute blood loss. Given that the two products were almost identical in properties and function, it was thought that the early release of Oxyglobin would create an unrealistic price expectation for Hemopure if released first. Oxyglobin Protein Hydrolysate has not demonstrated mutagenic potential in the Salmonella Thyphimurium reverse mutation assay Ames test. Company Description Biopure develops, manufactures and markets oxygen therapeutics.
If the competitors want to get a share for animal blood substitutes, they have to wait at least for two years. Dilute Oxyglobin Iron Ferrous Fumarate in a maximum of 250 mL of 0. When Hemopure is launched, the marketing and distribution issues encountered during Oxyglobin launch can be avoided. The manufacturer of Oxyglobin is using? Otherwise, if competitors with similar selling price appear, production cost and capacity will dominate the market share. He also admitted to posing as his doctor in a phone call with his lawyer so that she would tell the judge that his cancer had spread and that he was undergoing chemotherapy.
Partner with a larger pharmaceutical company in order to counter competitive disadvantages and to begin building brand relationships with end users. Do not administer Oxyglobin Iron Ferrous Fumarate to patients with Oxyglobin Iron Ferrous Fumarate overload. The code is based on Active ingredients of the medicine. To view content sources and attributions, please refer to our. A total of 5 11% subjects in the Oxyglobin Iron Ferrous Fumarate 0. Therefore, Biopure can only focus its target on emergency care practices market in the initial stage. The issue of a possible negative impact of launching now on the pricing of Hemopure is also addressed.
No distribution network in place. Marketing Plan for launching Oxyglobin Push and Pull strategy will be implemented to enhance the marketing plan of launching Oxyglobin. Biopure has also observed slight increases in blood pressure and abdominal discomfort in Hemopure-infused patients. Patient age and serum ferritin level were similar between treatment and historical control patients. The cease of using animal donors in these clinics will show that Oxyglobin is successfully replacing this old practice. No self generated revenues as on date.
. Administration of Oxyglobin Zinc Sulfate in the absence of copper may cause a decrease in serum copper levels. Because ascorbic acid increases iron absorption, its use in high doses can be dangerous in patients with hemochromatosis, thalassemia, polycythemia, leukemia, and sideroblastic anemia. A red blood cell transfusion is the standard therapy for anemia resulting from blood loss. It will be important for Biopure to educate buyers and present Hemopure as a differentiated product with superior quality as compared to the other competitive products entering the market. There is a concern about creating an unrealistic price expectation for Hemopure by marketing Oxyglobin before Hemopure. This method generally does not include blood typing and cross matching and has been shown to prolong the recovery of the animal because of this lack of preparation.
Recommendation 1 We recommend Biopure launch Oxyglobin into the veterinary market as soon as possible. In general, dose administration to an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Competition: Competition in the human blood market starts with the American Red Cross and other small providers that collect voluntary blood donations for transfusions. Gently swirl the vial until all powder is dissolved. We believe that Biopure should launch Oxyglobin now.